Atopic Dermatitis and Psoriasis

Presented by Peter A. Lio, MD

Question Title

* 1. Will this activity enhance your competence or encourage you do anything differently after attending?

Question Title

* 2. Will this activity influence your practice or patient outcomes?

Question Title

* 3. Was the presence of faculty conflict of interest or commercial support provided to the audience prior to the activity?

Question Title

* 4. Please share your impressions of the speaker and presentation by rating the following:

  Excellent Good Fair Poor
Presentation Style
Knowledge of Material
Relevance of Topic
Connection with Audience

Question Title

* 5. Are there any topics you would like to see covered in future webinars - and/or - would you like a follow up (perhaps to go more in-depth on one particular topic) to this session?

Question Title

* 6. What is your specialty?

Question Title

* 7. How many years have you been in practice?

Question Title

* 8. How many patients with AD do you manage?

Question Title

* 9. Please select the best option that best describes your practice setting:

Question Title

* 10. How confident are you in the management of patients with AD in your practice?  (Please answer before hearing the talk, and after hearing the talk.)

  Very confident Confident Neutral Slightly confident Not confident
Before hearing this talk
After hearing this talk

Question Title

* 11. How would you classify the severity of AD in a patient with perceptible erythema, papulation, and lichenification with mild oozing?

  Mild Moderate Severe
Before hearing this talk
After hearing this talk

Question Title

* 12. In addition to basic management comprising skin care and trigger avoidance, which of the following treatments would you prescribe for a patient with marked erythema, induration, and lichenification affecting 40% of the body, including the face and hands?

Question Title

* 13. What proportion of pediatric patients with moderate-to-severe AD do you think have been shown to achieve ≥75% improvement in lesion extent and severity when dupilumab is combined with TCS therapy?

  30% 50% 70%
Before hearing this talk
After hearing this talk

Question Title

* 14. How do you think the rate of ISGA (Investigator’s Static Global Assessment) success in crisaborole-treated infants 3 to <24 months compare with that observed in previous studies of similarly treated patients ≥ 2 years?

  Significantly greater Significantly lower Similar
Before hearing this talk
After hearing this talk

Question Title

* 15. Casey is a 7 year old with a 5 year history of mild-to-moderate AD. His parents report that, despite diligent treatment with a TCI, he frequently wakes up during the night due to itching, and that his behavior and academic performance at school are increasingly being affected. According to current best practice recommendations, what is the most appropriate next step for Casey?

Question Title

* 16. If you are seeking CME, please attest below: 

I watched the entire hour long webinar.

Question Title

* 17. Provide your full name and credentials and your email address.

0 of 17 answered
 

T